HAEMONETICS CORP/MASS (HAE) Stock Fundamental Analysis
NYSE:HAE - US4050241003 - Common Stock
53.785 USD
+0.11 (+0.21%)
Taking everything into account, HAE scores 5 out of 10 in our fundamental rating. HAE was compared to 190 industry peers in the Health Care Equipment & Supplies industry. HAE scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on HAE.
1. Profitability
1.1 Basic Checks
In the past year HAE was profitable.
HAE had a positive operating cash flow in the past year.
HAE had positive earnings in each of the past 5 years.
Each year in the past 5 years HAE had a positive operating cash flow.
1.2 Ratios
HAE has a Return On Assets of 6.63%. This is amongst the best in the industry. HAE outperforms 86.84% of its industry peers.
The Return On Equity of HAE (18.51%) is better than 93.16% of its industry peers.
With an excellent Return On Invested Capital value of 9.88%, HAE belongs to the best of the industry, outperforming 90.53% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for HAE is in line with the industry average of 8.46%.
The last Return On Invested Capital (9.88%) for HAE is above the 3 year average (8.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.63% | ||
| ROE | 18.51% | ||
| ROIC | 9.88% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
1.3 Margins
HAE's Profit Margin of 12.13% is amongst the best of the industry. HAE outperforms 87.89% of its industry peers.
In the last couple of years the Profit Margin of HAE has grown nicely.
HAE has a Operating Margin of 18.12%. This is amongst the best in the industry. HAE outperforms 88.95% of its industry peers.
In the last couple of years the Operating Margin of HAE has remained more or less at the same level.
Looking at the Gross Margin, with a value of 57.42%, HAE is in line with its industry, outperforming 55.79% of the companies in the same industry.
In the last couple of years the Gross Margin of HAE has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.12% | ||
| PM (TTM) | 12.13% | ||
| GM | 57.42% |
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so HAE is still creating some value.
The number of shares outstanding for HAE has been reduced compared to 1 year ago.
Compared to 5 years ago, HAE has less shares outstanding
The debt/assets ratio for HAE is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.24 indicates that HAE is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.24, HAE is in the better half of the industry, outperforming 65.26% of the companies in the same industry.
The Debt to FCF ratio of HAE is 7.62, which is on the high side as it means it would take HAE, 7.62 years of fcf income to pay off all of its debts.
HAE's Debt to FCF ratio of 7.62 is fine compared to the rest of the industry. HAE outperforms 76.32% of its industry peers.
A Debt/Equity ratio of 1.04 is on the high side and indicates that HAE has dependencies on debt financing.
HAE has a Debt to Equity ratio of 1.04. This is in the lower half of the industry: HAE underperforms 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | 7.62 | ||
| Altman-Z | 2.24 |
ROIC/WACC1.49
WACC6.62%
2.3 Liquidity
A Current Ratio of 1.72 indicates that HAE should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.72, HAE is doing worse than 70.53% of the companies in the same industry.
A Quick Ratio of 1.04 indicates that HAE should not have too much problems paying its short term obligations.
HAE has a worse Quick ratio (1.04) than 74.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 17.72% over the past year.
Measured over the past 5 years, HAE shows a small growth in Earnings Per Share. The EPS has been growing by 6.66% on average per year.
The Revenue has been growing slightly by 0.91% in the past year.
Measured over the past years, HAE shows a small growth in Revenue. The Revenue has been growing by 6.60% on average per year.
EPS 1Y (TTM)17.72%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%7.84%
Revenue 1Y (TTM)0.91%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-4.4%
3.2 Future
Based on estimates for the next years, HAE will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.55% on average per year.
HAE is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.86% yearly.
EPS Next Y6.62%
EPS Next 2Y10.13%
EPS Next 3Y10.55%
EPS Next 5YN/A
Revenue Next Year-4.73%
Revenue Next 2Y0.73%
Revenue Next 3Y2.86%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 11.57 indicates a reasonable valuation of HAE.
Based on the Price/Earnings ratio, HAE is valued cheaper than 91.58% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.03, HAE is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 9.70, the valuation of HAE can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HAE indicates a rather cheap valuation: HAE is cheaper than 93.16% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.54, HAE is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.57 | ||
| Fwd PE | 9.7 |
4.2 Price Multiples
HAE's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HAE is cheaper than 90.53% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HAE is valued cheaply inside the industry as 90.53% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.12 | ||
| EV/EBITDA | 9.8 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
HAE has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.75
PEG (5Y)1.74
EPS Next 2Y10.13%
EPS Next 3Y10.55%
5. Dividend
5.1 Amount
HAE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:HAE (9/11/2025, 2:59:49 PM)
53.785
+0.11 (+0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners118.25%
Inst Owner Change-2.81%
Ins Owners1.14%
Ins Owner Change9.02%
Market Cap2.59B
Analysts81.33
Price Target81.91 (52.29%)
Short Float %9.18%
Short Ratio5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.91%
Min EPS beat(2)0.62%
Max EPS beat(2)7.2%
EPS beat(4)4
Avg EPS beat(4)2.96%
Min EPS beat(4)0.62%
Max EPS beat(4)7.2%
EPS beat(8)7
Avg EPS beat(8)4%
EPS beat(12)11
Avg EPS beat(12)9.1%
EPS beat(16)14
Avg EPS beat(16)8.76%
Revenue beat(2)1
Avg Revenue beat(2)1.96%
Min Revenue beat(2)-0.63%
Max Revenue beat(2)4.55%
Revenue beat(4)1
Avg Revenue beat(4)0.38%
Min Revenue beat(4)-2.22%
Max Revenue beat(4)4.55%
Revenue beat(8)4
Avg Revenue beat(8)1.08%
Revenue beat(12)8
Avg Revenue beat(12)2.33%
Revenue beat(16)10
Avg Revenue beat(16)1.82%
PT rev (1m)-13.84%
PT rev (3m)-12.51%
EPS NQ rev (1m)-5.54%
EPS NQ rev (3m)-8.84%
EPS NY rev (1m)-0.85%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)-2.97%
Revenue NQ rev (3m)-6.15%
Revenue NY rev (1m)-1.13%
Revenue NY rev (3m)-1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.57 | ||
| Fwd PE | 9.7 | ||
| P/S | 1.93 | ||
| P/FCF | 16.12 | ||
| P/OCF | 11.44 | ||
| P/B | 2.94 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.8 |
EPS(TTM)4.65
EY8.65%
EPS(NY)5.54
Fwd EY10.31%
FCF(TTM)3.34
FCFY6.21%
OCF(TTM)4.7
OCFY8.74%
SpS27.94
BVpS18.31
TBVpS-3.65
PEG (NY)1.75
PEG (5Y)1.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.63% | ||
| ROE | 18.51% | ||
| ROCE | 12.63% | ||
| ROIC | 9.88% | ||
| ROICexc | 11.65% | ||
| ROICexgc | 32.9% | ||
| OM | 18.12% | ||
| PM (TTM) | 12.13% | ||
| GM | 57.42% | ||
| FCFM | 11.95% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
ROICexc(3y)10.46%
ROICexc(5y)8.47%
ROICexgc(3y)26.78%
ROICexgc(5y)22.33%
ROCE(3y)11.45%
ROCE(5y)9.23%
ROICexcg growth 3Y22.36%
ROICexcg growth 5Y7.33%
ROICexc growth 3Y21.7%
ROICexc growth 5Y-5.09%
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
F-Score8
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | 7.62 | ||
| Debt/EBITDA | 2.56 | ||
| Cap/Depr | 57.06% | ||
| Cap/Sales | 4.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 63.09% | ||
| Profit Quality | 98.45% | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z | 2.24 |
F-Score8
WACC6.62%
ROIC/WACC1.49
Cap/Depr(3y)79.52%
Cap/Depr(5y)76.24%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.58%
Profit Quality(3y)103.91%
Profit Quality(5y)115.34%
High Growth Momentum
Growth
EPS 1Y (TTM)17.72%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%7.84%
EPS Next Y6.62%
EPS Next 2Y10.13%
EPS Next 3Y10.55%
EPS Next 5YN/A
Revenue 1Y (TTM)0.91%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-4.4%
Revenue Next Year-4.73%
Revenue Next 2Y0.73%
Revenue Next 3Y2.86%
Revenue Next 5YN/A
EBIT growth 1Y18.51%
EBIT growth 3Y34.59%
EBIT growth 5Y7.12%
EBIT Next Year34.55%
EBIT Next 3Y15.63%
EBIT Next 5YN/A
FCF growth 1Y-8.53%
FCF growth 3Y16.98%
FCF growth 5Y2.09%
OCF growth 1Y-9.46%
OCF growth 3Y1.79%
OCF growth 5Y2.81%